This is a translation of the original article in Portuguese. Read the original (Português).
A large study with the substance diranersen showed that Alzheimer’s patients who received low doses had 54% less decline on a memory and reasoning test over almost two years. The information comes from the British newspaper The Times.
The treatment is an injection given only twice a year, which makes it more practical than therapies that require frequent applications. It works by reducing the tau protein, which is associated with the death of brain cells, one of the processes linked to the progression of the disease.
What the number means: the 54% reduction does not mean the disease was halted or that memory was recovered. It indicates that, in the group that received low doses, the drop in test performance was just over half of what was observed in those who did not receive this treatment during the follow-up period of almost two years.
The next step is set in the United Kingdom. Recruitment of British patients for a new trial is expected to begin in the spring. This type of stage serves to confirm, with more volunteers, whether the results hold and whether the treatment is safe.
What this changes for the Brazilian reader: for now, nothing in terms of access. Diranersen is a substance in the research phase, and there is no treatment with it available in Brazil’s public health system (SUS) or in the private network. The results also come from a study conducted with patients in another country, and any eventual arrival in Brazil would depend on the completion of the trials and the assessment of health authorities, steps that still have no date.
The news, nonetheless, matters to a growing number of middle-aged families and elderly people living with Alzheimer’s. It points to a treatment path that directly targets the tau protein and that, if confirmed, could require fewer visits to health services, with only two applications per year.
It is too early to talk about a cure or a change in the routine of patients and caregivers. The result is promising, but it needs to be repeated in larger studies before becoming a commonly used therapy.
Reporting from The Times (p. 10, caderno nacional (Reino Unido)).
Deixe um comentário